Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

McBride Ali; Krendyukov Andriy; Mathieson Nicola; Campbell Kim; Balu Sanjeev; MacDonald Karen; Abraham Ivo

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

【24h】

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

机译：与佩格菲尔格氏菌类药物失效相比，美国飞疱疹病效与非霍奇金淋巴瘤中的参考和生物仿制物菲拉特相比，美国飞口中性蛋白的住院成本模拟

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
McBride Ali; Krendyukov Andriy; Mathieson Nicola; Campbell Kim; Balu Sanjeev; MacDonald Karen; Abraham Ivo;
展开▼
作者单位

Univ Arizona Coll Pharm Dept Pharm Practice &

Sci Tucson AZ 85721 USA;

HEXAL AG Sandoz Biopharmaceut Holzkirchen Germany;

HEXAL AG Sandoz Biopharmaceut Holzkirchen Germany;

Sandoz Princeton NJ USA;

Sandoz Princeton NJ USA;

Matrix45 Tucson AZ USA;

Matrix45 Tucson AZ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献

1. Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma [J] . McBride Ali, Krendyukov Andriy, Mathieson Nicola, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：与佩格菲尔格氏菌类药物失效相比，美国飞疱疹病效与非霍奇金淋巴瘤中的参考和生物仿制物菲拉特相比，美国飞口中性蛋白的住院成本模拟
2. Comparison of effectiveness of biosimilar filgrastim (Nivestim (TM)), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study [J] . Brito M., Esteves S., Andre R., Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2016,第2期

机译：比较非生物仿制药非格司亭（Nivestim（TM）），参比剂Amgen非格司亭和聚乙二醇非格司亭在新（辅助）TAC治疗的乳腺癌患者发热性中性粒细胞减少症的一级预防中的有效性比较：一项非干预性队列研究
3. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. [J] . Matti Aapro, Paul Cornes, Ivo Abraham Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2012,第2期

机译：在欧洲五国集团（G5）国家中，非格司亭，仿制药非格司亭和吡格非司亭的不同治疗方案在降低化疗引起的发热性中性粒细胞减少症发病率方面具有相对的成本效益。
4. Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study [O] . Ramin Ravangard, Najme Bordbar, Khosro Keshavarz, 2017

机译：非霍奇金淋巴瘤患者的培格非司亭和非格司亭对发热性中性粒细胞减少症的初步预防：一项成本效果研究
5. PCN7 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN SPAIN [O] . Lopez A, Arocho R, Atchison C, 2007

机译：非霍奇金淋巴瘤患者接受CHOP-21治疗的PCN7对原发性中性神经减少症与PEGFILGRASTIM的原发性PROPROLAXIS与FILGRASTIM的成本效益比较

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

著录项

相似文献

相关主题

期刊订阅